News
Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy
Hanover, MD, and New York, NY, October 12, 2020 – The Sickle Cell Disease Association of America (SCDAA) and Aruvant Sciences are proud to announce
Aruvant to Present at Investor and Scientific Conferences in October
NEW YORK and BASEL, Switzerland, Sept. 29, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment
Aruvant Appoints Dr. Palaniappan as Chief Technology Officer
Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than
Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer
Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell
Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a
Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a
Aruvant Appoints William Chou as Chief Executive Officer
Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe
Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology
Two patients have been administered RVT-1801 in conjunction with reduced intensity conditioning regimens Both patients exhibit evidence of sustained, stable, genetically-modified cells in blood and
Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children’s Hospital Medical Center
BASEL, Switzerland and CINCINNATI November 26, 2018 | PRNewswire Roivant Sciences and Cincinnati Children’s Hospital Medical Center today announced the launch of Aruvant Sciences, a